1. Yu, F.#, Song, H.#, Wu, Y.#, Chang, S.Y., Wang, L., Xia, S., Hong, B., Li, W., Wang, C., Khurana, S., Feng, Y., Wang, Y., Sun, Z., He, B., Min, J.Y., Golding, H., J. X., Lu, L., Jiang, S., Dimiktrov, D., Ying, T.* (2017). A potent germline-like human monoclonal antibody targeting a novel pH-sensitive epitope on H7N9 influenza hemagglutinin. Cell Host Microbe. Accepted. IF=14.946.

2. Yu, Y., Deng, Y.Q., Zou, P., Wang, Q., Dai, Y., Yu, F., Du, L., Zhang, N.N., Tian, M., Hao, J.N., Meng, Y, Woo, J.F.W., Yuen, K.Y., Qin, C.F.*, Jiang, S.*, Lu, L.* (2017). A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses. Nat. Commun. 8, 15672. IF=12.124.

3. Qi, Q.#, Wang, Q.#, Chen, W., Du, L., Dimitrov, D.S., Lu, L.*, Jiang, S.* (2017). HIV-1 gp120-targeting bispecific multivalent proteins effectively inactivated HIV-1 virions when used alone or in combination with gp41-targeting fusion inhibitory peptides. Emer. Microb. Infect. 6(6):e59. IF=5.605.

4. Li, H., Yu, F., Xia, S., Yu, Y., Wang, Q., Lv, M., Wang, Y., Jiang, S.*, Lu, L.* (2017). Chemically modified human serum albumin exhibits potent inhibitory activity against Ebola virus infection. Antimicrob. Agents Chemother. 61(4): e02168-16. IF=4.302.

5. Su, S., Zhu, Y., Ye, S., Qi, Q., Xia, S., Ma, Z., Yu, F., Wang, Q., Zhang, R., Jiang, S.*, Lu, L.* (2017). Creating an artificial tail-anchor as a novel strategy to enhance the potency of peptide-based HIV fusion inhibitors. J. Virol. 91(1): e01445-16. IF=4.663.

6. Su, S., Wang, Q., Xu, W., Yu, F., Hua, C., Zhu, Y., Jiang, S.*, Lu, L.* (2017). A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity. AIDS. 31(7):885-894. IF=5.003.

7. Qi, Q., Wang, Q., Chen, W., Yu, F., Du, L., Dimitrov, D.S., Lu, L.*, Jiang, S.* (2017). Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains. J. Infect. 75(1):68-71. IF=4.201.

8. Li, W., Lu, L., Li, W., Jiang, S.* (2017). Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015). Expert Opin. Ther. Pat.27(6):707-719. IF=3.041.

9. Xu, W., Li, H., Wang, Q., Hua, C., Zhang, H., Li, W., Jiang, S.*, Lu, L.*,(2017). Advancements in developing strategies for sterilizing and functional HIV cures. Biomed. Res. Int. 2017:6096134. IF=2.476.

10. Xu, W., Daia, Y., Hua, C., Wang, Q., Zou, P., Deng, Q., Jiang, S.*, Lu, L.*. (2017). Genomic signature analysis of the recently emerged highly pathogenic A(H5N8) avian influenza virus: implying an evolutionary trend for bird-to-human transmission. Microb. Infect. Sep 7. pii: S1286-4579(17)30121-1. doi: 10.1016/j.micinf.2017.08.006. [Epub ahead of print]. IF=2.125.

11. Jiang, S.*, Ojcius, D. (2017). Combating Flu in China. Microb. Infect. Oct 6. pii: S1286-4579(17)30157-0. doi: 10.1016/j.micinf.2017.09.013. [Epub ahead of print]. IF=2.125.